ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
N/A
Address
Level 14 333 Collins Street Melbourne, Victoria (VIC) 3000
Description
Adherium Ltd. engages in the development, manufacture, and supply of digital health technologies. It operates through the following geographical segments: New Zealand and Australia, South-East Asian Countries, and Other Countries. The firm's Hailie system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. The company was founded by Garth Sutherland in 2001 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.03
Trade Value (12mth)
US$1,993.00
1 week
0%
1 month
-11.11%
YTD
-42.86%
1 year
-57.89%
All time high
10.31
EPS 3 yr Growth
-88.50%
EBITDA Margin
%
Operating Cashflow
-$11m
Free Cash Flow Return
-134.80%
ROIC
-129.90%
Interest Coverage
-5,802.20
Quick Ratio
2.40
Shares on Issue (Fully Dilluted)
758m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
NZD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
08 May 25 |
Adherium Expands Leadership Team
×
Adherium Expands Leadership Team |
|
08 May 25 |
Initial Director's Interest Notice - K Gessner
×
Initial Director's Interest Notice - K Gessner |
|
08 May 25 |
Final Director's Interest Notice - W Hunter
×
Final Director's Interest Notice - W Hunter |
|
30 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
29 April 25 |
Results of Extraordinary General Meeting
×
Results of Extraordinary General Meeting |
|
07 April 25 |
Notification of cessation of securities - ADR
×
Notification of cessation of securities - ADR |
|
28 March 25 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
|
21 March 25 |
Board and Executive Leadership Update
×
Board and Executive Leadership Update |
|
19 March 25 |
Notification regarding unquoted securities - ADR
×
Notification regarding unquoted securities - ADR |
|
18 March 25 |
Adherium Secures $2.6M to Advance Smart Inhaler in US
×
Adherium Secures $2.6M to Advance Smart Inhaler in US |
|
18 March 25 |
Investor Presentation
×
Investor Presentation |
|
18 March 25 |
Proposed issue of securities - ADR
×
Proposed issue of securities - ADR |
|
18 March 25 |
Proposed issue of securities - ADR
×
Proposed issue of securities - ADR |
|
17 March 25 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
|
07 March 25 |
Management Change - Update
×
Management Change - Update |
|
28 February 25 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
|
27 February 25 |
Change in substantial holding
×
Change in substantial holding |
|
31 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
09 December 24 |
Notification regarding unquoted securities - ADR
×
Notification regarding unquoted securities - ADR |
|
05 December 24 |
Adherium, AMC Health partner for Improved Respiratory Care
×
Adherium, AMC Health partner for Improved Respiratory Care |
|
04 December 24 |
Partnership with Tenovi for Remote Patient Monitoring
×
Partnership with Tenovi for Remote Patient Monitoring |
|
04 December 24 |
Adherium Secures R&D Loan Facility
×
Adherium Secures R&D Loan Facility |
|
15 November 24 |
Results of Meeting
×
Results of Meeting |
|
15 November 24 |
Amended Constitution
×
Amended Constitution |
|
31 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
